<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378729</url>
  </required_header>
  <id_info>
    <org_study_id>P051008</org_study_id>
    <nct_id>NCT00378729</nct_id>
  </id_info>
  <brief_title>Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)</brief_title>
  <acronym>PERCING</acronym>
  <official_title>PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hopital Antoine Beclere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Jean Verdier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jean Rostand Intercommoned Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lille Hospital : Jeanne de Flandre Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strasbourg Hospital : Civil Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CMCO SIHCUS, Schiltingheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Study and research center of sterility (Lyon)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PolysCsytic Ovaries Syndrome (PCOS) is the most frequent endocrinopathy. The first stage of
      infertility treatment is Clomiphene Citrate which leads to 50 % pregnancies. In case of
      failure, it is possible to propose surgical ovarian drilling or ovarian hyperstimulation with
      Intra Uterine Insemination (IUI) which lead to 50% pregnancies each. However, surgical
      treatment could be associated to surgical complications, and medical treatment could be
      associated to ovarian hyperstimulation syndrome and/or multiple pregnancies.

      The aim of this study is to compare the two treatments to demonstrate the equivalence of
      efficacy and the diminution of multiple pregnancies by the surgical treatments. After an
      ambulatory surgery we will observe the spontaneous fertility during 9 months. For the medical
      treatment, Metformin is proposed during 9 months associated with 3 cycles of ovarian
      hyperstimulation and IUI if the sperm is normal
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PolysCsytic Ovaries Syndrome (PCOS) is the most frequent endocrinopathy. The first stage of
      infertility treatment is Clomiphene Citrate which leads to 50 % pregnancies. In case of
      failure, it is possible to propose surgical ovarian drilling or ovarian hyperstimulation with
      Intra Uterine Insemination (IUI) which lead to 50% pregnancies each. However, surgical
      treatment could be associated to surgical complications, and medical treatment could be
      associated to ovarian hyperstimulation syndrome and/or multiple pregnancies.

      The aim of this study is to compare the two treatments to demonstrate the equivalence of
      efficacy and the diminution of multiple pregnancies by the surgical treatments. After an
      ambulatory surgery we will observe the spontaneous fertility during 9 months. For the medical
      treatment, Metformin is proposed during 9 months associated with 3 cycles of ovarian
      hyperstimulation and IUI if the sperm is normal Ovarian drilling will be performed by
      FERTILOSCOPY. 126 patients will be necessary in each group (with interval of equivalence :
      10%).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the cumulative rate of on-going pregnancy (&gt;12 weeks of amenorrhoea) obtained during 9 months of follow-up</measure>
    <time_frame>during 9 months of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tolerance</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of multiple pregnancies</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the menstrual cycles and hormonal ovarian dosages</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of spontaneous miscarriages</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index with each visit</measure>
    <time_frame>at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and FSHr</intervention_name>
    <description>treatment for infertility</description>
    <arm_group_label>A</arm_group_label>
    <other_name>treatment for infertility</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian drilling by FERTILOSCOPY</intervention_name>
    <description>surgical ovarian drilling</description>
    <arm_group_label>B</arm_group_label>
    <other_name>surgical ovarian drilling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 36 years old

          -  Female patient with PCOS (Rotterdam criteria)

          -  Failure of treatment with Clomiphene Citrate

          -  Informed consent

          -  Female patient with medical assurance

          -  Patient in failure with PCOS and Clomiphene citrate

        Exclusion Criteria:

          -  Female patient is over 36 years old

          -  Thyroid disease (4&lt;TSH&lt;0.3 mUI/L)

          -  Virilizing tumor

          -  FERTILOSCOPY non possible (Douglas cul de sac clinically fixed)

          -  Anormality of SPERMOGRAM (abnormal time of migration of survival)

          -  Prolactin &gt; 1.5 N

          -  Anormality of 17-OH Progesterone (&lt;2 ng/mL)

          -  Fallopian tubes non permeable TMS&lt; 5 Millions

          -  Female patient participant or have been participated to another clinical trial during
             the last month before the inclusion

          -  Female patient without medical assurance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé FERNANDEZ, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hervé FERNANDEZ, MD,PhD</last_name>
    <phone>+33(0)- 1 45 37 44 69</phone>
    <email>herve.fernandez@abc.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé FERNANDES, MD,PhD</last_name>
      <phone>+33(0)- 1 45 37 44 69</phone>
      <email>herve.fernandez@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé FERNANDEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Fernandez H, Watrelot A, Alby JD, Kadoch J, Gervaise A, deTayrac R, Frydman R. Fertility after ovarian drilling by transvaginal fertiloscopy for treatment of polycystic ovary syndrome. J Am Assoc Gynecol Laparosc. 2004 Aug;11(3):374-8.</citation>
    <PMID>15559352</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>October 3, 2011</last_update_submitted>
  <last_update_submitted_qc>October 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>FERTILOSCOPY</keyword>
  <keyword>Ovarian hyperstimulation</keyword>
  <keyword>Multiple pregnancies</keyword>
  <keyword>Patient with PCOS (Rotterdam criteria)</keyword>
  <keyword>Failure of treatment with Clomiphene Citrate</keyword>
  <keyword>Age between 18 and 36 years old</keyword>
  <keyword>Spermogram must be normal</keyword>
  <keyword>Permeability of Fallopian tubes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

